Stem Cell Authority Ltd(SCAL)
USD --+0.00%
Reward49Moderate
Risk47Moderate
📊50%Data
Strong 55% profit margin
SCAL
+0.0 · +0.00%
USD · PINK
Stem Cell Authority Ltd | Healthcare
Balanced
Market Cap:97085
ℹ️
Reward Rating
49
Moderate
Bottom 50% (model universe)
50% data coverage
ℹ️
Risk Rating
47
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on SCAL to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Stem Cell Authority Ltd?

, a technology development company, focuses on the collection and cryogenic preservation of stem cells.

SCAL · Verdict

Moderate reward · moderate risk

SCAL stands out on balance sheet and volatility, but watch the cash flow signal.

Based on 75% data coverage

SCAL · Verdict

What’s working & what to watch

Strengths 2

  • Balance sheet89/100

    Top decile vs peers

  • Volatility75/100

    Above average

Watchouts 2

  • Cash flow5/100

    Weak vs peers

  • Profitability36/100

    0% return on equity

Model-based scoring. For information only — not financial advice.

What is Stem Cell Authority Ltd?

, a technology development company, focuses on the collection and cryogenic preservation of stem cells. It specializes in the collection and cryogenic preservation of the hematopoietic stem cells from the umbilical cord blood; and the Miracle Mesenchymal stem cells from the Wharton's jelly inside the umbilical cord of a newborn child. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 97.08K.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (49)

The scoring profile indicates limited reward potential at this time, with valuation and growth offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap97.08K
P/E Ratio0.02
Dividend YieldN/A
52 Week High0.0002
52 Week Low0.0001
Last AnnualAugust
IPO DateN/A
IncorporatedUSA
Shares Outstanding971M
No. of EmployeesN/A
IndustryMedical Care Facilities
ExchangePINK
Beta-1.112
CurrencyUSD